Cover Image
市場調查報告書

MorphoSys AG - 產品平台分析

MorphoSys AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 204920
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
MorphoSys AG - 產品平台分析 MorphoSys AG - Product Pipeline Review - 2015
出版日期: 2015年02月28日 內容資訊: 英文 40 Pages
簡介

MorphoSys AG 是開發治療、診斷以及研究用途的單株抗體之生物科技企業。同時也與其他製藥公司或生物科技企業合作,主要提供癌症及關節風溼老年痴呆症等治療藥。

本報告提供MorphoSys AG 的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

MorphoSys AG的基本資料

MorphoSys AG概要

  • 主要資訊
  • 企業資料

MorphoSys AG:R&D概要

  • 主要的治療範圍

MorphoSys AG:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

MorphoSys AG:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

MorphoSys AG:藥物簡介

  • MOR-208
  • NOV-3
  • MOR-202
  • BI-1
  • CNTO-5
  • NOV-7
  • PFE-1
  • Monoclonal Antibodies For MRSA Infections
  • Monoclonal Antibody for Oncology
  • MOR-206

MorphoSys AG:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

MorphoSys AG:最近的開發平台趨勢

MorphoSys AG:暫停中的計劃

MorphoSys AG:中止開發的開發中產品

  • 中止開發的開發中產品簡介
  • MOR-203
  • MOR-101
  • MOR-102

MorphoSys AG:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06830CDB

Summary

Global Markets Direct's, 'MorphoSys AG - Product Pipeline Review - 2015', provides an overview of the MorphoSys AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of MorphoSys AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of MorphoSys AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of MorphoSys AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the MorphoSys AG's pipeline products

Reasons to buy

  • Evaluate MorphoSys AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of MorphoSys AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the MorphoSys AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of MorphoSys AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of MorphoSys AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of MorphoSys AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • MorphoSys AG Snapshot
    • MorphoSys AG Overview
    • Key Information
    • Key Facts
  • MorphoSys AG - Research and Development Overview
    • Key Therapeutic Areas
  • MorphoSys AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • MorphoSys AG - Pipeline Products Glance
    • MorphoSys AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • MorphoSys AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • MorphoSys AG - Drug Profiles
    • MOR-208
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MOR-202
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for MRSA Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize GPCR for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • MorphoSys AG - Pipeline Analysis
    • MorphoSys AG - Pipeline Products by Target
    • MorphoSys AG - Pipeline Products by Route of Administration
    • MorphoSys AG - Pipeline Products by Molecule Type
    • MorphoSys AG - Pipeline Products by Mechanism of Action
  • MorphoSys AG - Recent Pipeline Updates
  • MorphoSys AG - Dormant Projects
  • MorphoSys AG - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • MOR-203
      • MOR-101
      • MOR-102
  • MorphoSys AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • MorphoSys AG, Key Information
  • MorphoSys AG, Key Facts
  • MorphoSys AG - Pipeline by Indication, 2015
  • MorphoSys AG - Pipeline by Stage of Development, 2015
  • MorphoSys AG - Monotherapy Products in Pipeline, 2015
  • MorphoSys AG - Partnered Products in Pipeline, 2015
  • MorphoSys AG - Partnered Products/ Combination Treatment Modalities, 2015
  • MorphoSys AG - Out-Licensed Products in Pipeline, 2015
  • MorphoSys AG - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • MorphoSys AG - Phase II, 2015
  • MorphoSys AG - Phase I, 2015
  • MorphoSys AG - Preclinical, 2015
  • MorphoSys AG - Discovery, 2015
  • MorphoSys AG - Pipeline by Target, 2015
  • MorphoSys AG - Pipeline by Route of Administration, 2015
  • MorphoSys AG - Pipeline by Molecule Type, 2015
  • MorphoSys AG - Pipeline Products by Mechanism of Action, 2015
  • MorphoSys AG - Recent Pipeline Updates, 2015
  • MorphoSys AG - Dormant Developmental Projects,2015
  • MorphoSys AG - Discontinued Pipeline Products, 2015
  • MorphoSys AG, Subsidiaries

List of Figures

  • MorphoSys AG - Pipeline by Top 10 Indication, 2015
  • MorphoSys AG - Pipeline by Stage of Development, 2015
  • MorphoSys AG - Monotherapy Products in Pipeline, 2015
  • MorphoSys AG - Partnered Products in Pipeline, 2015
  • MorphoSys AG - Pipeline by Top 10 Target, 2015
  • MorphoSys AG - Pipeline by Top 10 Route of Administration, 2015
  • MorphoSys AG - Pipeline by Top 10 Molecule Type, 2015
  • MorphoSys AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top